A "hot" topic in dyslipidemia management-"how to beat a flush": Optimizing Niacin tolerability to promote long-term treatment adherence and coronary disease prevention

Mayo Clinic Proceedings

Volumn 85, Issue 4, 2010, Pages 365-379

  Jacobson, Terry A ^a  

^a Department of Medicine   (United States)

Author keywords

HDL C = high density lipoprotein cholesterol; NSAID = nonsteroidal anti inflammatory drug; PG = prostaglandin; RCT = randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; ENDUR ACIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; PLACEBO; PROSTAGLANDIN D2; SLO NIACIN; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; HEAT; HUMAN; MEDLINE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRURITUS; REVIEW; SIDE EFFECT; SKIN REDNESS; SKIN TINGLING;

EID: 77950670133     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2009.0535     Document Type: Review

References (150)

1. Adult Treatment Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(106):3143-3421.
2. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007; 14 (Suppl 2) : S1-S113. (Pubitemid 47339826)
3. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94(94):706-714.
4. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem. 1955;54(54):558-559.
5. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(8):1245-1255.
6. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(231):360-381.
7. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery: two-and four-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88(88):20-28.
8. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257(257):3233-3240.
9. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(323):1289-1298.
10. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(345):1583-1592.
11. McKenney J. Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm. 2003;60(60):995-1005.
12. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142(142):95-104.
13. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(361):2113- 2122.
14. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22(22):2243-2250.
15. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(110):3512-3517.
16. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol. 2000; 86 (12A) : 51L-56L.
17. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008; 101 (8A) : 20B-26B.
18. Knowles HJ, te Poele RH, Workman P, Harris AL. Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol. 2006;71(71):646-656.
19. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164(164):697-705.
20. Simons LA. Treatment of lipids: implications for the general practitioner. Aust Fam Physician. 1996;25(25):1053-1059.
21. Abughosh SM, Kogut SJ, Andrade SE, Larrat P, Gurwitz JH. Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm. 2004;10(10):404-411.
22. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(288):462-467.
23. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(288):455-461.
24. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(279):1458-1462.
25. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332(332):1125-1131.
26. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a populationbased retrospective cohort study in Israel. Clin Ther. 2008;30(30):2167-2179.
27. LaFleur J, Thompson CJ, Joish VN, Charland SL, Oderda GM, Brixner DI. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extendedrelease niacin. Ann Pharmacother. 2006; 40 (7-8) : 1274-1279.
28. Kamal-Bahl S, Watson DJ, Ambegaonkar BM. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview. Clin Ther. 2009;31(31):130-140.
29. Kamal-Bahl SJ, Burke TA, Watson DJ, Wentworth CE. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin. 2008;24(24):1817-1821.
30. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34(34):642-650.
31. Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003;139(139):996-1002.
32. Abbott. Niaspan® (niacin extended-release). US full prescribing information. http://www.rxabbott.com/pdf/niaspan. pdf. Accessed May 18, 2009.
33. Abbott. Simcor® (niacin extended-release/simvastatin). US full prescribing information. http://www.rxabbott.com/pdf/simcor-pi.pdf. Accessed May 18, 2009.
34. Abbott. Advicor® (niacin extended-release/lovastatin tablets). US full prescribing information. Available at http://www.rxabbott.com/pdf/advicor. pdf. Accessed May 18, 2009.
35. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol. 2006;126(126):2637-2646.
36. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115(115):3634-3640.
37. Pike NB. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest. 2005;115(115):3400-3403.
38. Morrow JD, Parsons WG III, Roberts LJ. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins. 1989;38(38):263-274.
39. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103(103):6682-6687.
40. Benyo Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol. 2006;70(70):1844-1849.
41. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother. 2004;5(5):1385-1398.
42. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000; 86 (12A) : 35L-40L.
43. Stern RH. The role of nicotinic acid metabolites in flushing and hepatotoxicity. J Clin Lipidol. 2007;1:191-193.
44. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271(271):672-677.
45. Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med. 1991;91(91):239-246.
46. Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther. 1991;50(50):66-70.
47. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(258):94-114.
48. Guyton JR, Simmons PD. Flushing and other dermatologic adverse events associated with extended-release niacin therapy. J Clin Lipidol. 2009;3:101-108.
49. Davidson MH. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol. 2008; 101 (8A) : 14B-19B.
50. Goldberg AC. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol. 2004;94(94):121-124.
51. Kawata AK, Revicki DA, Thakkar R, et al. Flushing ASsessment Tool (FAST) : psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Clin Drug Investig. 2009;29(29):215-229.
52. Norquist JM, Watson DJ, Yu Q, Paolini JF, McQuarrie K, Santanello NC. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin. 2007;23(23):1549-1560.
53. Paolini JF, Mitchel YB, Reyes R, et al. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. Int J Clin Pract. 2008;62(62):896-904.
54. Insull W Jr, Basile JN, Vo AN, Jiang P, Thakkar R, Padley RJ. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: the SUPREME study. J Clin Lipidol. 2009;3:109-118.
55. Ballantyne CM, Davidson M, McKenney JM, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008;2:79-90.
56. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101(101):1428-1436.
57. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008;8(8):69-81.
58. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol. 2008;51(51):1564-1572.
59. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192(192):432-437.
60. Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extendedrelease niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med. 2004;164(164):1121- 1127.
61. Capuzzi DM, Morgan JM, Carey CM, et al. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol. 2004;7(7):176-181.
62. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol. 2003;91(91):1304- 1310.
63. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol. 2003;91(91):667-672.
64. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89(89):672-678.
65. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan) : a long-term study. Am J Cardiol. 1998; 82 (12A) : 74U-81U.
66. Keenan JM, Bae CY, Fontaine PL, et al. Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. J Am Geriatr Soc. 1992;40(40):12-18.
67. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151(151):1424-1432.
68. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial. Arch Intern Med. 2002;162(162):1568-1576.
69. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan) : dose-escalation study. Am J Cardiol. 1998; 82 (12A) : 35U-38U.
70. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a timerelease form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47(47):1097-1104.
71. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan) : efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998; 82 (suppl 12A) : 29U-34U.
72. Cefali EA, Simmons PD, Stanek EJ, Shamp TR. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther. 2006;44(44):633-640.
73. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82(82):737-743.
74. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(45):185-197.
75. Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on highdensity lipoprotein in patients undergoing long-term statin therapy. Am Heart J. 2002;143(143):514-518.
76. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA. 2000;284(284):1263-1270.
77. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80(80):111-115.
78. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol. 1997;79(79):1298-1301.
79. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995;76(76):480-484.
80. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154(154):73-82.
81. King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med. 1994;97(97):323-331.
82. O'Kane MJ, Trinick TR, Tynan MB, Trimble ER, Nicholls DP. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br J Clin Pharmacol. 1992;33(33):451-453.
83. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. JAMA. 1990;264(264):723-726.
84. Aronov DM, Keenan JM, Akhmedzhanov NM, Perova NV, Oganov RY, Kiseleva NY. Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med. 1996;5(5):567-575.
85. Vacek JL, Dittmeier G, Chiarelli T, White J, Bell HH. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 1995;76(76):182-184.
86. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustainedrelease niacin therapy in patients with "isolated" very low levels of highdensity lipoprotein cholesterol and coronary artery disease. Am J Cardiol. 1992;69(69):1083-1085.
87. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144(144):165-172.
88. Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994;73(73):339-345.
89. Poldermans D, Dunkelgrun M, Schouten O, Hostalek U. Prolonged-release nicotinic acid in patients with atherosclerotic disease in the Netherlands. Eur Surg Res. 2008;41(41):313-318.
90. Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol. 2004;94(94):306-311.
91. Lin TH, Voon WC, Yen HW, et al. Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in Taiwan. Kaohsiung J Med Sci. 2006;22(22):257-265.
92. Sharma M, Sharma DR, Singh V, et al. Evaluation of efficacy and safety of fixed dose lovastatin and niacin (ER) combination in Asian Indian dyslipidemic patients: a multicentric study. Vasc Health Risk Manag. 2006;2(2):87-93.
93. Dube MP, Wu JW, Aberg JA, et al. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir Ther. 2006;11(11):1081-1089.
94. Pan J, Van JT, Chan E, Kesala RL, Lin M, Charles MA. Extendedrelease niacin treatment of the atherogenic lipid profile and lipoprotein (a) in diabetes. Metabolism. 2002;51(51):1120-1127.
95. Kane MP, Hamilton RA, Addesse E, Busch RS, Bakst G. Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. Pharmacotherapy. 2001;21(21):1473-1478.
96. Harikrishnan S, Rajeev E, Tharakan JA, et al. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart J. 2008;60:215-222.
97. Birjmohun RS, Kastelein JJ, Poldermans D, Stroes ES, Hostalek U, Assmann G. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin. 2007;23(23):1707-1713.
98. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin. 2006;22(22):417-425. (Pubitemid 44296766)
99. Guyton JR, Blazing MA, Hagar J, et al; Niaspan-Gemfibrozil Study Group. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160(160):1177-1184.
100. Chojnowska-Jezierska J, Adamska-Dyniewska H. Efficacy and safety of one-year treatment with slow-release nicotinic acid:onitoring of drug concentration in serum. Int J Clin Pharmacol Ther. 1998;36(36):326-332.
101. Luria MH. Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med. 1988;148(148):2493-2495.
102. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121(121):252-258.
103. Squires RW, Allison TG, Gau GT, Miller TD, Kottke BA. Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol. Mayo Clin Proc. 1992;67(67):855-860.
104. McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM; Collaborative Atorvastatin Study Group. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998;104(104):137-143.
105. Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol. 1989;64(64):725-729.
106. Jelesoff NE, Ballantyne CM, Xydakis AM, Chiou P, Jones PH, Guyton JR. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia. Endocr Pract. 2006;12(12):159-164.
107. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med. 1995;99(99):378-385.
108. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin: a randomized placebo-controlled trial. BMC Clin Pharmacol. 2003;3:4-11.
109. Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med. 1996;156(156):1081-1088.
110. Lal SM, Hewett JE, Petroski GF, Van Stone JC, Ross G Jr. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis. 1995;25(25):616-622.
111. Tsalamandris C, Panagiotopoulos S, Sinha A, Cooper ME, Jerums G. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk. 1994;1(1):231-239.
112. Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994;74(74):149-154.
113. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol. 1994;73(73):25D-29D.
114. Schectman G, Hiatt J, Hartz A. Evaluation of the effectiveness of lipid-lowering therapy (bile acid sequestrants, niacin, psyllium and lovastatin) for treating hypercholesterolemia in veterans. Am J Cardiol. 1993;71(71):759-765.
115. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264(264):3007-3012.
116. Rindone JP, Arriola OG. Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic. Pharmacotherapy. 1997;17(17):296-1299.
117. Gardner SF, Marx MA, White LM, Granberry MC, Skelton DR, Fonseca VA. Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control. Ann Pharmacother. 1997;31(31):677-682.
118. Duvall WL, Blazing MA, Saxena S, Guyton JR. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. J Cardiovasc Risk. 2002;9(9):339-347.
119. Taher TH, Dzavik V, Reteff EM, Pearson GJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol. 2002;89(89):390-394.
120. Olsen S, Smith S, Oei T, Douglas J. Health belief model predicts adherence to CPAP before experience with CPAP. Eur Respir J. 2008;32(32):710-717.
121. Wai CT, Wong ML, Ng S, et al. Utility of the Health Belief Model in predicting compliance of screening in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2005;21(21):1255-1262.
122. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q. 1988;15(15):175-183.
123. Becker MH, Radius SM, Rosenstock IM, Drachman RH, Schuberth KC, Teets KC. Compliance with a medical regimen for asthma: a test of the health belief model. Public Health Rep. 1978;93(93):268-277.
124. Moon YS, Kashyap ML. Niacin extended-release/lovastatin: combination therapy for lipid disorders. Expert Opin Pharmacother. 2002;3(3):1763-1771.
125. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007; 99 (6A) : 22C-31C.
126. Brown WV, Goldberg AC, Guyton JR, Knopp RH. Clinical lipidology roundtable: the use of niacin. J Clin Lipidol. 2009;3:65-69.
127. American Society of Health-System Pharmacists. ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. Am J Health Syst Pharm. 1997;54(54):2815-2819.
128. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 2004; 22 (Suppl 3) : 13-23.
129. Cefali EA, Simmons PD, Stanek EJ, McGovern ME, Kissling CJ. Aspirin reduces cutaneous flushing after administration of an optimized extendedrelease niacin formulation. Int J Clin Pharmacol Ther. 2007;45(45):78-88.
130. Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs. 2009;9(9):69-79.
131. Alves JD, Steinhagen-Thiessen E, Darioli R, Hostalek U, Vogt A. Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk. Curr Med Res Opin. 2008;24(24):2815-2820.
132. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med. 1997;12(12):591-596.
133. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther. 1995;2(2):478-480.
134. Whelan AM, Price SO, Fowler SF, Hauler BL. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract. 1992;34(34):165-168.
135. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract. 2006;60(60):707-715.
136. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther. 2008;83(83):840-847.
137. Lai E, DeLepeleire I, Crumley TM, et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther. 2007;81(81):849-857.
138. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol. 2009;49(49):416-422.
139. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101(101):625-630.
140. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62(62):1959-1970.
141. Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin. 2008;26(26):547-560.
142. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009;104(104):74-81.
143. Ding RW, Kolbe K, Merz B, de Vries J, Weber E, Benet LZ. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther. 1989;46(46):642-647.
144. EMEA. CHMP Assessment Report for Tredaptive: European Medicines Agency, Evaluation of Medicines for Human Use. Doc. Ref. : EMEA/348364/2008 ed. London, UK: European Medicines Agency; 2008.
145. Kalogeromitros D, Makris M, Chliva C, Aggelides X, Kempuraj D, Theoharides TC. A quercetin containing supplement reduces niacin-induced flush in humans. Int J Immunopathol Pharmacol. 2008;21(21):509-514.
146. Papaliodis D, Boucher W, Kempuraj D, Theoharides TC. The flavonoid luteolin inhibits niacin-induced flush. Br J Pharmacol. 2008;153(153):1382-1387.
147. Shen HC, Ding FX, Deng Q, et al. Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats. J Med Chem. 2009;52(52):2587-2602.
148. Meier AS, Richardson BA, Hughes JP. Discrete proportional hazards models for mismeasured outcomes. Biometrics. 2003;59(59):947-954.
149. Turnbull BW. The empirical distribution function with arbitrarily grouped, censored, and truncated data. J R Stat Soc B. 1976;38:290-295.
150. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal. 1999;21:383-392.